Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065507941> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2065507941 endingPage "35" @default.
- W2065507941 startingPage "S" @default.
- W2065507941 abstract "associated with an increased risk of neoplastic progression. Aim: To compare the prevalence of DNA promoter hypermethylation in esophageal biopsies of BE patients with residual BE (ND or LGD) after endoscopic ablation therapy versus patients who present with BE and ND or LGD at baseline and have never been treated. Methods: Using a prospective large BE cohort of 220 patients followed over the past 6 years, we performed a case-control study comparing two groups of patients: 1) patients with BE and high-grade dysplasia and/or intramucosal adenocarcinoma who were treated with photodynamic therapy and had residual BE [ND or LGD as the highest grade of dysplasia on follow-up upper endoscopies], and 2) patients with a baseline diagnosis of BE (ND or LGD) who had never undergone endoscopic therapy. All patients had undergone endoscopic surveillance with the Seattle biopsy protocol. Esophageal biopsies of BE from residual disease in group 1 and at baseline in group 2 were analyzed using methylation-specific PCR, and the prevalence of p16 and APC promoter methylation was compared. Results: There were 15 patients with residual BE (ND or LGD) after photodynamic therapy and 82 patients who presented with BE and ND or LGD at baseline and had never been treated. Patients with residual BE (ND or LGD) after ablation had a significantly higher prevalence of DNAmethylation compared to patients who presented with BE and ND or LGD at baseline for both p16 (73% vs. 31%; OR [95% CI]=6.1 [1.7521.2]; p<0.01) and APC (80% vs. 50%; OR [95% CI]=4.0 [1.0-15.3]; p=0.04). Conclusions: Since DNA methylation is a strong predictor of subsequent neoplastic progression to highgrade dysplasia or esophageal adenocarcinoma, the high prevalence of DNA methylation seen in patients with residual BE (ND or LGD) after endoscopic ablation suggest that these patients may have a higher risk of neoplastic progression compared to patients who have an initial presentation of BE and ND or LGD at baseline and have never been treated. Therefore, residual BE (ND or LGD) after endoscopic ablation should likely be managed more aggressively than de novo BE with ND or LGD." @default.
- W2065507941 created "2016-06-24" @default.
- W2065507941 creator A5005368164 @default.
- W2065507941 creator A5012188262 @default.
- W2065507941 creator A5015617830 @default.
- W2065507941 creator A5020423194 @default.
- W2065507941 creator A5054398705 @default.
- W2065507941 creator A5058959601 @default.
- W2065507941 date "2010-05-01" @default.
- W2065507941 modified "2023-09-23" @default.
- W2065507941 title "189 Treatment of Experimental Colitis Using Adenovirus-Directed Expression of Prohibitin" @default.
- W2065507941 doi "https://doi.org/10.1016/s0016-5085(10)60160-6" @default.
- W2065507941 hasPublicationYear "2010" @default.
- W2065507941 type Work @default.
- W2065507941 sameAs 2065507941 @default.
- W2065507941 citedByCount "0" @default.
- W2065507941 crossrefType "journal-article" @default.
- W2065507941 hasAuthorship W2065507941A5005368164 @default.
- W2065507941 hasAuthorship W2065507941A5012188262 @default.
- W2065507941 hasAuthorship W2065507941A5015617830 @default.
- W2065507941 hasAuthorship W2065507941A5020423194 @default.
- W2065507941 hasAuthorship W2065507941A5054398705 @default.
- W2065507941 hasAuthorship W2065507941A5058959601 @default.
- W2065507941 hasConcept C203014093 @default.
- W2065507941 hasConcept C2775862500 @default.
- W2065507941 hasConcept C2775894526 @default.
- W2065507941 hasConcept C28859421 @default.
- W2065507941 hasConcept C502942594 @default.
- W2065507941 hasConcept C70721500 @default.
- W2065507941 hasConcept C86803240 @default.
- W2065507941 hasConcept C95444343 @default.
- W2065507941 hasConceptScore W2065507941C203014093 @default.
- W2065507941 hasConceptScore W2065507941C2775862500 @default.
- W2065507941 hasConceptScore W2065507941C2775894526 @default.
- W2065507941 hasConceptScore W2065507941C28859421 @default.
- W2065507941 hasConceptScore W2065507941C502942594 @default.
- W2065507941 hasConceptScore W2065507941C70721500 @default.
- W2065507941 hasConceptScore W2065507941C86803240 @default.
- W2065507941 hasConceptScore W2065507941C95444343 @default.
- W2065507941 hasIssue "5" @default.
- W2065507941 hasLocation W20655079411 @default.
- W2065507941 hasOpenAccess W2065507941 @default.
- W2065507941 hasPrimaryLocation W20655079411 @default.
- W2065507941 hasRelatedWork W2014234675 @default.
- W2065507941 hasRelatedWork W2093919096 @default.
- W2065507941 hasRelatedWork W2111463022 @default.
- W2065507941 hasRelatedWork W2146665033 @default.
- W2065507941 hasRelatedWork W2342093593 @default.
- W2065507941 hasRelatedWork W2922969401 @default.
- W2065507941 hasRelatedWork W3007525382 @default.
- W2065507941 hasRelatedWork W3082882401 @default.
- W2065507941 hasRelatedWork W3126623926 @default.
- W2065507941 hasRelatedWork W4292170728 @default.
- W2065507941 hasVolume "138" @default.
- W2065507941 isParatext "false" @default.
- W2065507941 isRetracted "false" @default.
- W2065507941 magId "2065507941" @default.
- W2065507941 workType "article" @default.